Previous 10 | Next 10 |
home / stock / bmymp / bmymp news
Halozyme is currently in the stalwart phase with approximately less than 50% more upsides. The company shifted focus to employing a low-risk business model. They're out-licensing their Enhanze technology to other large pharmas. With an increasing number of blockbusters being refor...
AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...
This technology-focused healthcare infrastructure platform connects payors, providers, and employers in an efficient and analytical way. As a new growth-based company seeing 40% CAGR revenues over the past two years, net income remains negative but profitability is higher than their p...
I manage two portfolios, the first holds "risky" thematic technology, biotech, and high growth companies. The second is my sleep well at night portfolio, holding the majority of my assets. Growth has certainly been out of favor lately and my SWAN portfolio has more than held its own r...
bluebird bio's new therapies have strict labels due to health concerns over severe side effects, limiting the addressable markets of these new therapies. Toxicities of bluebird's new therapies point to shortcomings of its CAR-T and Leniglobin technology, lowering the economic moat of ...
My passive income increased by 13.59% year over year in April. I made 17 purchases and 2 sales. My performance continues to lag the market on a year-to-date basis due to an overweight allocation towards technology, but long term, I still really like my positioning. For furth...
Thinking long term is a requirement to hold big winners in a portfolio. Beyond patience, you need the stomach to go through the volatility. The drawdowns you have to cope with can be incredibly heart wrenching. Winners only appear in hindsight. I review examples of the pas...
Fisher’s 13F portfolio value increased from ~$133.5B to ~$142B in Q1 2021. They increased Walt Disney and Eli Lilly while trimming Taiwan Semi, JD.com, and Pinduoduo. Fisher has a number of small positions in several ETFs/ETNs. For further details see: Tracking Ke...
Bristol-Myers Squibb Company (BMY) Q1 2021 Earnings Conference Call April 29, 2021 10:00 AM ET Company Participants Tim Power – Vice President-Investor Relations Giovanni Caforio – Board Chair and Chief Executive Officer David Elkins – Chief Financial Officer Samit Hirawa...
The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2021 Q1 earnings call. For further details see: Bristol-Myers Squibb Company 2021 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb $2Pr Company Name:
BMYMP Stock Symbol:
OTCMKTS Market:
Bristol-Myers Squibb $2Pr Website: